Liraglutide
A GLP-1 receptor agonist FDA-approved for diabetes (Victoza) and weight management (Saxenda), the predecessor to semaglutide.
What is Liraglutide?
Liraglutide is a GLP-1 receptor agonist with 97% homology to native human GLP-1. It was the first GLP-1 agonist approved for weight management (Saxenda, 3mg daily) and is also approved for type 2 diabetes (Victoza, 1.8mg daily). While largely superseded by semaglutide, it remains widely used with extensive long-term safety data.
What Liraglutide Is Investigated For
Liraglutide is FDA-approved for type 2 diabetes (Victoza, 2010) and chronic weight management (Saxenda, 2014), with the LEADER trial (2016) additionally establishing a 13% reduction in major adverse cardiovascular events — the first cardiovascular mortality benefit demonstrated for the GLP-1 class. The strongest evidence is across all three indications: the LEAD program for T2D, the SCALE program for obesity (~8% mean weight loss at 56 weeks on 3.0 mg), and LEADER for CV outcomes all involved thousands of patients with over 15 years of post-marketing safety data. Liraglutide has been clinically superseded by semaglutide and tirzepatide on weight-loss magnitude (STEP-8 showed semaglutide produced roughly twice the weight loss) and convenience (weekly vs daily), but it retains meaningful niches: the longest real-world safety record in the class, genuine pediatric approvals (now including children 6 to under 12), and emerging generic availability that shifts the cost calculus. Like all GLP-1 agonists, weight is largely regained within 1–2 years of discontinuation, and the thyroid C-cell tumor boxed warning and pancreatitis signals apply class-wide.
History & Discovery
Liraglutide was developed by Novo Nordisk as the second long-acting GLP-1 receptor agonist to reach market (after exenatide twice-daily) and represented a structural breakthrough — a GLP-1 analog with 97% homology to the native human peptide, modified by addition of a C-16 palmitic acid side chain that enabled reversible albumin binding and extended the half-life from 2 minutes (native GLP-1) to approximately 13 hours. The FDA approved Victoza for type 2 diabetes in January 2010 following the LEAD (Liraglutide Effect and Action in Diabetes) program of six Phase III trials. The higher-dose Saxenda formulation (3.0 mg daily) gained FDA approval for chronic weight management in December 2014, the first GLP-1 agonist indicated specifically for obesity. The landmark LEADER cardiovascular outcomes trial, published in 2016, demonstrated a 13% relative reduction in major adverse cardiovascular events over 3.8 years in type 2 diabetes patients, establishing the first cardiovascular mortality benefit for the GLP-1 class and setting the template for subsequent CVOT trials in the class. Liraglutide has largely been clinically superseded by once-weekly semaglutide and tirzepatide on efficacy and convenience grounds, but it retains one of the longest real-world safety records in the class and is expected to enter generic availability as key patents expire during 2024–2026.
How It Works
Like semaglutide, liraglutide mimics the GLP-1 hormone to reduce appetite, slow digestion, and improve blood sugar control. It requires daily injection because it has a shorter duration of action.
Liraglutide activates GLP-1R with a C-16 fatty acid (palmitic acid) modification enabling albumin binding and extending half-life to ~13 hours (vs 2 minutes for native GLP-1). Same downstream signaling as semaglutide but with lower receptor occupancy due to daily dosing and shorter half-life. The LEADER cardiovascular outcomes trial demonstrated 13% reduction in MACE events.
Evidence Snapshot
Human Clinical Evidence
Extensive. LEAD, SCALE, and LEADER trial programs. 10+ years of post-marketing data.
Animal / Preclinical
Comprehensive.
Mechanistic Rationale
Very strong. Same GLP-1R mechanism as semaglutide.
Research Gaps & Open Questions
What the current literature has not yet settled about Liraglutide:
- 01Long-term pediatric data in young populations — new approvals for children 6 to under 12 (Ella trial) are recent, and long-term metabolic and developmental outcomes are still accruing.
- 02Generic-to-branded equivalence in real-world practice — as liraglutide generics enter the market, real-world comparative effectiveness and switching data are not yet mature.
- 03Comparative effectiveness of daily vs once-weekly GLP-1 agonists in specific populations — whether any patients benefit from daily dosing over once-weekly (for tolerability or pharmacodynamic reasons) remains underexplored.
- 04Liraglutide in neuropsychiatric indications — early signals in Alzheimer's disease (EVOKE for semaglutide, ELAD for liraglutide) warrant continued investigation; liraglutide's shorter half-life may matter for these indications.
- 05Post-discontinuation metabolic rebound — well-documented for weight but less quantified for glycemic, CV, and renal outcomes.
Forms & Administration
Daily SC injection. Victoza: 0.6-1.8mg/day for T2D. Saxenda: 0.6-3.0mg/day for weight management. Dose titration over 4-5 weeks. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
For Victoza (type 2 diabetes), the FDA-labeled schedule begins at 0.6 mg once daily for at least 1 week (a non-therapeutic initiation dose for tolerability), increases to 1.2 mg once daily, and may be further titrated to 1.8 mg once daily if glycemic targets are not met. For Saxenda (chronic weight management), titration is slower: 0.6 mg daily for 1 week, then 1.2, 1.8, 2.4, and finally 3.0 mg daily as the maintenance dose, with each step lasting 1 week, reaching maintenance by week 5. The full Saxenda dose is 3.0 mg daily.
Frequency
Once daily by subcutaneous injection, at any time of day (morning, evening, or meal-associated) as long as the same approximate time is maintained day-to-day. Unlike once-weekly semaglutide or tirzepatide, a missed daily dose cannot be meaningfully 'made up' — if more than 12 hours have elapsed, patients are instructed to skip and resume at the next scheduled dose.
Timing Considerations
Time of day
Once daily at approximately the same time each day. Morning is common; evening is equally valid. The ~13-hour half-life is short enough that consistent clock time matters more than with weekly GLP-1 analogs.
Relative to meals
With or without food. GLP-1-class nausea may feel more manageable when the injection is not paired with a large meal.
Relative to exercise
Unrelated to training.
Cycle Length
Liraglutide is intended for indefinite chronic use in both the Victoza and Saxenda indications. Weight regain after discontinuation is well-documented in SCALE extension data and mirrors the broader GLP-1 class pattern: the majority of lost weight returns within 1–2 years in the absence of other interventions. The underlying diabetes or obesity is chronic, and the pharmacological effect ends shortly after the drug clears.
Protocol Notes
Liraglutide is supplied as a pre-filled multi-dose pen injector — no reconstitution is required. The Saxenda pen includes 0.6, 1.2, 1.8, 2.4, and 3.0 mg dose settings on a single pen, allowing titration without changing pen strength. Injection sites are abdomen, thigh, or upper arm, with rotation to minimize injection-site reactions. The 5-week titration for Saxenda is driven primarily by GI tolerability; nausea and vomiting concentrate at each upward step and typically attenuate within several days. Compared to once-weekly agents, liraglutide's daily dosing creates more consistent but less convenient pharmacokinetic exposure, which some patients prefer for tolerability reasons. As generic versions enter the US market during 2024–2026 under AB-rated approvals, formulation and pen-device details may vary across manufacturers.
These doses reflect FDA-labeled protocols for specific indications. Individual dosing, titration pacing, and continuation decisions require clinician supervision and individualized evaluation.
Timeline of Effects
Onset
Appetite suppression is reported within the first few days of initiation, though at the non-therapeutic 0.6 mg starting dose the effect is typically modest. HbA1c improvement appears within 2–4 weeks. Measurable weight loss on Saxenda generally begins during the titration phase and accelerates once the 3.0 mg maintenance dose is reached at week 5.
Peak Effect
In the SCALE Obesity and Prediabetes trial (n=3,731), mean weight loss at 56 weeks with Saxenda 3.0 mg was 8.0%, compared to 2.6% with placebo; approximately 33% of participants lost ≥10% body weight. The LEAD program for Victoza established HbA1c reductions of 1.0–1.5 percentage points at the 1.8 mg dose. Weight-loss curves with Saxenda generally plateau around month 9–12, which is modest compared to semaglutide or tirzepatide but meaningful for many patients. The STEP-8 head-to-head trial directly compared weekly semaglutide 2.4 mg to daily liraglutide 3.0 mg and showed semaglutide produced approximately twice the weight loss (15.8% vs 6.4%).
After Discontinuation
SCALE extension and real-world data show a pattern broadly consistent with the rest of the GLP-1 class: majority of lost weight is regained within 12–24 months of stopping, with reversion of HbA1c, blood pressure, and lipid markers toward baseline. Liraglutide's shorter half-life means pharmacokinetic clearance is complete within roughly 3 days of the last injection; the behavioral and metabolic effects unwind over the following weeks to months as appetite and satiety signaling return to baseline.
Monitoring & Measurement
Bloodwork & Labs
- •HbA1c — primary glycemic endpoint at 3-month intervals
- •Fasting glucose and fasting insulin (HOMA-IR)
- •Lipid panel (total, LDL, HDL, triglycerides)
- •ALT and AST
- •Lipase and amylase at baseline
Functional & Performance Tests
- •Body weight (same scale, weekly)
- •Waist circumference
- •Home blood pressure cuff
When to Test
Baseline, 12 weeks, 24 weeks; weight weekly.
Interpretation & Notes
The SCALE trial anchors expectations: about 8% weight loss at week 56 on 3.0 mg. Liraglutide's response is meaningfully smaller than semaglutide or tirzepatide — if you're not a responder by week 16 (less than 4% loss), switching to a longer-acting analog is often more productive than dose escalation. Daily injection makes adherence the biggest practical differentiator. Same pancreatitis and gallbladder cautions as the rest of the class. Standard metabolic and lipid panels via LabCorp/Quest direct-to-consumer.
Common Questions
Who Liraglutide Is NOT For
- •Personal or family history of medullary thyroid carcinoma (MTC) — boxed warning shared across the incretin class, based on rodent C-cell tumor findings.
- •Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — genetic predisposition to medullary thyroid carcinoma makes this an absolute contraindication.
- •Prior serious hypersensitivity reaction (anaphylaxis, angioedema) to liraglutide or any component of the formulation.
- •Active pancreatitis or history of recurrent pancreatitis — post-marketing signals for acute pancreatitis have been reported, and the class warning applies.
- •Pregnancy — animal reproductive toxicity data exists; the labeling advises discontinuation once pregnancy is recognized.
- •Breastfeeding — transfer into human milk is not adequately characterized; weigh risk-benefit with the prescribing clinician.
- •Severe gastroparesis or significant gastrointestinal motility disorders — delayed gastric emptying can worsen symptoms and rarely precipitate obstruction.
- •Pediatric use below approved age cutoffs — Victoza is approved for type 2 diabetes in patients 10 and older; Saxenda is approved for chronic weight management in adolescents 12 and older; younger pediatric use is not approved outside of specific investigational settings.
- •Concurrent use with other GLP-1 receptor agonists — redundant mechanism, amplified GI and hypoglycemia risk, no incremental benefit.
Drug & Supplement Interactions
The two principal clinical interaction domains are hypoglycemia risk and altered oral drug absorption. Combined with insulin or insulin secretagogues (sulfonylureas, meglitinides), liraglutide materially raises hypoglycemia risk; downward adjustment of those agents at liraglutide initiation and each titration step is typically required. Delayed gastric emptying can alter the rate and sometimes the extent of absorption of orally administered drugs — most clinically relevant for warfarin (INR monitoring after dose changes), levothyroxine (TSH monitoring), and orally administered antibiotics and antiepileptics. Liraglutide has been specifically studied for oral contraceptive pharmacokinetics and appears to have less pronounced interaction than tirzepatide, though modest reductions in drug exposure have been reported. Concurrent use with SGLT2 inhibitors, metformin, and DPP-4 inhibitors is generally well-tolerated and does not require dose adjustment of liraglutide itself. Patients on any chronic oral regimen should review timing and monitoring with their prescribing clinician; liraglutide's 15+ years of post-marketing pharmacovigilance provides the most mature interaction dataset in the class.
Safety Profile
Common Side Effects
Cautions
- • Thyroid C-cell tumor warning
- • Pancreatitis risk
- • Gallbladder disease
- • Renal impairment monitoring
What We Don't Know
Well-characterized safety profile with 10+ years of post-marketing data.
Legal Status
United States
Liraglutide is FDA-approved as Victoza (January 2010) for adults and pediatric patients 10 years and older with type 2 diabetes, and as Saxenda (December 2014) for chronic weight management in adults and adolescents 12 and older with obesity. Key patents protecting liraglutide's exclusivity have begun to expire, and generic liraglutide entered the US market in 2024 under AB-rated approvals, making it the first GLP-1 agonist to go generic. Availability of compounded liraglutide is legally more constrained than for semaglutide or tirzepatide, since Victoza and Saxenda have not been on FDA shortage lists and generics are now available. Liraglutide remains under less active compounding pressure than the newer molecules as a consequence.
International
Liraglutide is authorized by the EMA (Victoza 2009, Saxenda 2015), UK MHRA, Health Canada, Australia's TGA, and numerous other regulators for parallel indications. NICE has reimbursement criteria for Saxenda that have historically been restrictive in England but have loosened as obesity pharmacotherapy has expanded. Generic availability is emerging in parallel jurisdictions on timelines roughly aligned with the US.
Sports & Competition
Liraglutide is not currently listed by name on the WADA Prohibited List. GLP-1 agonists generally fall into an ambiguous regulatory space with respect to sport: WADA has signaled rising scrutiny given the weight-management applications. Athletes in weight-category or endurance sports should consult their governing body before use.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Liraglutide is obsolete now that semaglutide and tirzepatide exist.
Reality
Liraglutide is less potent than the newer molecules on weight-loss outcomes, but it retains clinical niches: the longest real-world safety record in the class, genuine pediatric and adolescent approvals (including the recent Ella trial in children 6 to under 12), established cardiovascular outcomes data from LEADER, and emerging generic availability that materially changes the cost calculus. For some patients — cost-sensitive, daily-dosing-preferring, or requiring a molecule with a longer post-marketing history — liraglutide remains the better choice.
Myth
Victoza and Saxenda are different drugs.
Reality
Victoza and Saxenda are the same molecule — liraglutide — at different maximum doses (1.8 mg vs 3.0 mg) and with different FDA-approved indications (T2D vs chronic weight management). The clinical label determines indication, dosing schedule, and insurance coverage, but the active pharmaceutical ingredient is identical.
Myth
Because liraglutide has to be injected daily, it must cause more side effects than weekly agents.
Reality
Daily dosing creates more consistent pharmacokinetic exposure with less peak-to-trough variation than once-weekly agents, which for some patients translates to fewer GI side effects rather than more. The trade-off is convenience, not tolerability. Direct head-to-head data (STEP-8 for liraglutide vs semaglutide in obesity) showed comparable GI adverse event profiles between the two dosing frequencies.
Myth
Liraglutide is safer for children because it's been around longer.
Reality
'Around longer' in adults does not automatically extend to pediatric safety. Liraglutide's pediatric approvals (T2D for 10+, obesity for 12+, and more recently for children 6 to under 12 in the Ella trial context) are backed by specific pediatric studies — but those studies are comparatively small and short-duration relative to the adult dataset. Pediatric use requires pediatric-specific evidence, which has accrued gradually rather than transferring automatically from adult safety data.
Published Research
33 studiesLiraglutide for adults living with obesity
Genetic and physiological insights into satiation variability predict responses to obesity treatment
A randomized, double-blind, placebo-controlled trial of weight loss using liraglutide 3.0 mg for weight recurrence after Roux-en-Y gastric bypass
Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial
Safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta-analysis
Liraglutide Improves Myocardial Perfusion and Energetics and Exercise Tolerance in Patients With Type 2 Diabetes
Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial
Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: Results from a randomized clinical trial
Effects of Liraglutide, Empagliflozin and Their Combination on Left Atrial Strain and Arterial Function
Liraglutide for Lower Limb Perfusion in People With Type 2 Diabetes and Peripheral Artery Disease: The STARDUST Randomized Clinical Trial
Liraglutide in Obese or Overweight Individuals With Stable Bipolar Disorder
Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes
Glycemia and Gluconeogenesis With Metformin and Liraglutide: A Randomized Trial in Youth-onset Type 2 Diabetes
Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes
Liraglutide restores impaired associative learning in individuals with obesity
Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial
Evaluating potential predictors of weight loss response to liraglutide in adolescents with obesity: A post hoc analysis of the randomized, placebo-controlled SCALE Teens trial
Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes
Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial
Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study
Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study)
Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity
Efficacy and safety of liraglutide for obesity and people who are overweight: a systematic review and meta-analysis of randomized controlled trials
Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes
Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes
Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment
Effects of liraglutide on gastrointestinal functions and weight in obesity: A randomized clinical and pharmacogenomic trial
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial
The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis
Liraglutide for weight management: a critical review of the evidence
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Cost effectiveness of liraglutide in type II diabetes: a systematic review
Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme
Quick Facts
- Class
- GLP-1 Receptor Agonist
- Tier
- A
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Mar 2026
- Citations
- 33PubMed
Also known as
Tags
Peptide Families
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.